Bharat Book Bureau Provides the Trending Industry Research Report on“Therapeutic Nuclear Medicines Market - Global Outlook and Forecast 2022-2028”under Life Sciences Market Research Report. The report offers a collection of superior Market research, Market analysis, competitive intelligence and Market reports.
Executive Summary
Radioactive material, called radiopharmaceuticals, can be used to treat certain conditions. This is called nuclear medicine therapy.
Therapeutic nuclear medicines are a pharmaceutical formulation that consists of radioactive substances (radioisotopes). Therapeutic nuclear medicines are intending for the treatment of cancer, metastatic bone pain and other diseases. The radioactive material of therapeutic nuclear medicines is capable of killing the cancerous tissue, reducing the size of a tumor and reducing pain.
This report contains market size and forecasts of Therapeutic Nuclear Medicines in global, including the following market information:
Global Therapeutic Nuclear Medicines Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Therapeutic Nuclear Medicines Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Therapeutic Nuclear Medicines companies in 2021 (%)
The global Therapeutic Nuclear Medicines market was valued at 1719.4 million in 2021 and is projected to reach US$ 5230.4 million by 2028, at a CAGR of 17.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Radium-223 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Therapeutic Nuclear Medicines include Novartis AG, Bayer, China Isotope & Radiation, Q BioMed, Curium Pharmaceuticals, Jubilant DraxImage, Dongcheng, Lantheus and Acrotech Biopharma., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Therapeutic Nuclear Medicines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Therapeutic Nuclear Medicines Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Therapeutic Nuclear Medicines Market Segment Percentages, by Type, 2021 (%)
Radium-223
Lutetium-177
Iodine-131
Other
Global Therapeutic Nuclear Medicines Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Therapeutic Nuclear Medicines Market Segment Percentages, by Application, 2021 (%)
Thyroid
Bone Metastasis
Lymphoma
Other
Global Therapeutic Nuclear Medicines Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Therapeutic Nuclear Medicines Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Therapeutic Nuclear Medicines revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Therapeutic Nuclear Medicines revenues share in global market, 2021 (%)
Key companies Therapeutic Nuclear Medicines sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Therapeutic Nuclear Medicines sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis AG
Bayer
China Isotope & Radiation
Q BioMed
Curium Pharmaceuticals
Jubilant DraxImage
Dongcheng
Lantheus
Acrotech Biopharma.
Progenics Pharmaceuticals
Browse our full report with Table of Content : https://www.bharatbook.com/report/1265540/therapeutic-nuclear-medicines-market-global-outlook-and-forecast
About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 15,00,000 reports and insights that includes latest Industry Study, Industry Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: poonam@bharatbook.com
Website: www.bharatbook.com
According to a new market study by Future Market Insights (FMI), the global therapeutic nuclear medicines market will expand at a healthy rate between 2018 and 2028.The growth of the market is majorly attributed to factors such as the growing acceptance rate of therapeutic nuclear medicines, also known as radiopharmaceuticals, among consumers and medical professionals.
These medicines have proven to be largely free of negative side-effects and minimal risk factors.Furthermore, the rising prevalence of prostate cancer is acting as a major growth attribute to the market.
As the per statistics of the U.K. cancer research organization, prostate cancer is the most prevalent cancer among men with over 47,151 cases being diagnosed in 2015.
Likewise, the American Cancer Society states that prostate cancer is the most common cause of death in the US.
As the demand for safer, reliable, and less harmful drugs continues to increase in cancer treatment, therapeutic nuclear medicines are finding significant adoption among cancer patients.
Along similar lines, continually increasing incidence of bone metastases is also bolstering the growth of the market.“Owing to the stringent regulations by the US Food and Drugs Administration (FDA), market players are working on complying with the guidelines to receive approvals”, opines FMI analyst.For more insights into the Market, Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2930Therapeutic Nuclear Medicines Market – Key TakeawaysThe global therapeutic nuclear medicines market will expand at an impressive CAGR of 9.7% through the forecast period.Radium-223 is expected to remain the most prescribed drug by medical professionals, accounting for nearly 78% of the market share in overall market value.Erbium-169 is forecasted to gain prominence through the forecast period owing to increased usage in the treatment of liver cancer.Prostate cancer will remain the dominant indication type, accounting for more than 50% of overall market value owing to high incidence.Bone metastases is expected to remain a lucrative segment while brain tumor and thyroid cancer are forecasted to emerge as significant indication types through the forecast period.Therapeutic Nuclear Medicines Market – Key TrendsLaunch of novel drug formulations has been identified as the major trend in the therapeutic nuclear medicines market.For instance, the introduction of Xofigo (Radium-223) and Lutathera (Lutetium-177) for the treatment of prostate cancer, neuroblastoma, and synovitis has proven effective and is bestowing lucrative revenue opportunities.For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-2930Therapeutic Nuclear Medicines Market – Regional AnalysisNorth America and Western Europe are forecasted to cumulatively account for nearly 2/3rd of overall market value share.Emerging economies such as Asia Pacific, Latin America, and Middle East & Africa are anticipated to register higher growth than developed economies, with Asia Pacific forefronting developing economies.In Asia Pacific, China is expected to register the huge growth owing to the widening cancer patient pool in the country and continual innovations by manufacturers in the region.Therapeutic Nuclear Medicines Market – Competitive LandscapeKey players operating in the market include some of the key players profiled in the therapeutic nuclear medicines market report include Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, Inc., ANSTO, Lantheus Medical Imaging, Inc., Eckert & Ziegler and International Isotopes Inc.
